Influenza immunisation coverage from 2015 to 2017: A national study of adult patients from Australian general practice.


Journal

Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899

Informations de publication

Date de publication:
18 07 2019
Historique:
received: 19 03 2019
revised: 16 05 2019
accepted: 18 06 2019
pubmed: 30 6 2019
medline: 20 9 2020
entrez: 30 6 2019
Statut: ppublish

Résumé

To assess influenza immunisation rates and coverage in adult patients from Australian general practice and identify whether practice or patients' characteristics are associated with vaccination uptake. Open cohort study. 550 Australian general practices included in the MedicineInsight database. Patients aged 18+ years who had at least one consultation during influenza season between 2015 and 2017. Two samples were considered: (1) 'active' patients (at least three consultations in any two consecutive years) and (2) 'every year' patients (at least one consultation per year). Influenza vaccination rates per 1,000 consultations and coverage (% vaccinated among those who consulted) from 2015 to 2017. Between 2015 and 2017 the influenza vaccine rate changed from 57.4 to 51.7 and 67.0 per 1,000 consultations, while correspondent values for coverage were 29.3%, 25.2% and 27.6% (in 'active' patients). Vaccine coverage was at least 30% higher in inner regional areas, among patients aged 65+ years or those with comorbidities. Similar associations were found among 'every year' patients, but average coverage across the three years was higher (41% vs 27%). Aboriginal and Torres Strait Islander people, either with or without comorbidity, showed a vaccine coverage 10-30% higher than non-Indigenous people for those aged less than 65 years (p-value for interaction < 0.001). MedicineInsight data is a useful and low-cost method to monitor influenza immunisation coverage. Independent of the sample used, vaccination coverage among Indigenous people or patients with comorbidities could be improved. Targeted strategies for high-risk groups need to be developed.

Identifiants

pubmed: 31253446
pii: S0264-410X(19)30819-9
doi: 10.1016/j.vaccine.2019.06.057
pii:
doi:

Substances chimiques

Influenza Vaccines 0

Types de publication

Historical Article Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4268-4274

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Carla De Oliveira Bernardo (C)

Discipline of General Practice, Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia. Electronic address: carla.bernardo@adelaide.edu.au.

David Alejandro González-Chica (DA)

Discipline of General Practice, Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia; Adelaide Rural Clinical School, The University of Adelaide, Adelaide, SA, Australia.

Monique Chilver (M)

The Australian Sentinel Practices Research Network (ASPREN), The University of Adelaide, Adelaide, SA, Australia.

Nigel Stocks (N)

Discipline of General Practice, Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia; Australian Partnership for Preparedness Research on Infectious Disease Emergencies (APPRISE) Centre of Research Excellence, NHMRC, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH